GSK
NEWS
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessing the gut could drive more promising drug development has led to the formation of a new company, Kintai Therapeutics.
The U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Dovato, a once-a-day, single-tablet combination of dolutegravir (DTG) and lamivudine (3TC) for HIV-1 in adults who had not received treatment before.
Cytovant licenses East Asian rights for a research-stage T cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene’s dendritic cell (DC) vaccine for the treatment of patients across East Asia
Partnering with Hong Kong-based Sinovant Sciences, which is one of Ramaswamy’s “vant” companies, Roivant and Sinovant are launching a company called Cytovant Sciences.
ViiV Healthcare, presented three-year data from the SWORD 1 and 2 clinical trials in HIV. The data was presented at the 25th Annual Conference of the British HIV Association (BHIVA) in Bournemouth, UK.
The late-stage studies funded by the financing round could set the stage for two potential regulatory approvals if the data remains strong.
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
JOBS
IN THE PRESS